KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Deferred Taxes: 2012-2024

Historic Deferred Taxes for Regeneron Pharmaceuticals (REGN) over the last 13 years, with Dec 2024 value amounting to $757.3 million.

  • Regeneron Pharmaceuticals' Deferred Taxes rose 65.24% to $278.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $833.1 million, marking a year-over-year increase of 9.13%. This contributed to the annual value of $757.3 million for FY2024, which is 9.61% down from last year.
  • Regeneron Pharmaceuticals' Deferred Taxes amounted to $757.3 million in FY2024, which was down 9.61% from $837.8 million recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Deferred Taxes registered a high of $837.8 million during FY2023, and its lowest value of -$75.6 million during FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' Deferred Taxes averaged around $780.5 million, with its median value being $757.3 million (2024).
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Deferred Taxes slumped by 157.89% in 2020, and later soared by 407.41% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Deferred Taxes (Yearly) stood at -$75.6 million in 2020, then spiked by 294.58% to $147.1 million in 2021, then spiked by 407.41% to $746.4 million in 2022, then climbed by 12.25% to $837.8 million in 2023, then declined by 9.61% to $757.3 million in 2024.